For HER2 mutation, we found that both trastuzumab and lapatinib were effective in OS and trastuzumab was also good in short-term PFS, yet lapatinib had a higher risk of adverse events and trastuzumab exhibited mediocre performace in controlling all adverse events except neutropenia. The gene discussed is ERBB2; the disease is neutropenia.